Semaglutide Enclomaphine Citrate
1 Inquiries
910463-93-3
Pharmaceutical Grade
99%
shenzhen
25 mg/12.5mg
2023-12-29
Semaglutide,Tirzepatide,Retatrutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
HYDROXYLAMINE 7
CAS No.:910463-93-3
Categories:
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Semaglutide,Tirzepatide,Retatrutide
-
Location:
Room 806, Yuanjian Business Building, Xuefu Road, Wuhua District, Kunming City, Yunnan Province
-
Payment Terms:
TT against copy of documents,D/P,D/A,O/A,TT against B/L draft before shipment
-
Average lead Time:
5
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2019
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Semaglutide Enclomaphine Citrate
5 KG Nov 26, 2023 Post an enquiry for this product
